Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$135.90 USD
-1.03 (-0.75%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $135.97 +0.07 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Income Statements
Fiscal Year end for Ascendis Pharma AS falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 289 | 54 | 9 | 8 | 15 |
Cost Of Goods | 48 | 13 | 4 | 0 | 0 |
Gross Profit | 241 | 41 | 5 | 8 | 15 |
Selling & Adminstrative & Depr. & Amort Expenses | 734 | 633 | 540 | 386 | 269 |
Income After Depreciation & Amortization | -493 | -592 | -535 | -378 | -254 |
Non-Operating Income | 28 | 36 | 85 | -9 | 11 |
Interest Expense | 48 | 53 | 5 | 92 | 1 |
Pretax Income | -513 | -609 | -454 | -479 | -244 |
Income Taxes | 8 | 6 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -521 | -614 | -454 | -479 | -244 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -521 | -614 | -454 | -479 | -244 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -473 | -573 | -516 | -367 | -246 |
Depreciation & Amortization (Cash Flow) | 20 | 19 | 18 | 11 | 7 |
Income After Depreciation & Amortization | -493 | -592 | -535 | -378 | -254 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 56.29 | 56.08 | 54.80 | 50.62 | 46.51 |
Diluted EPS Before Non-Recurring Items | -9.24 | -10.96 | -8.28 | -9.46 | -5.25 |
Diluted Net EPS (GAAP) | -9.25 | -10.96 | -8.28 | -9.46 | -5.25 |
Fiscal Year end for Ascendis Pharma AS falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 148.66 | 52.28 | 51.68 | 36.05 |
Cost Of Goods | NA | 20.95 | 8.04 | 14.10 | 4.96 |
Gross Profit | NA | 127.71 | 44.24 | 37.58 | 31.09 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 166.65 | 190.53 | 191.14 | 185.32 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -38.94 | -146.29 | -153.56 | -154.23 |
Non-Operating Income | NA | -47.56 | -2.89 | 30.87 | 47.13 |
Interest Expense | NA | 0.27 | 26.69 | 10.18 | 10.56 |
Pretax Income | NA | -86.76 | -175.86 | -132.88 | -117.66 |
Income Taxes | NA | 6.28 | 0.70 | -0.47 | 1.39 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -93.04 | -176.56 | -132.41 | -119.06 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -93.04 | -176.56 | -132.41 | -119.06 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 56.56 | 56.27 | 56.22 | 56.09 |
Diluted EPS Before Non-Recurring Items | NA | -1.66 | -3.12 | -2.35 | -2.12 |
Diluted Net EPS (GAAP) | NA | -1.64 | -3.14 | -2.36 | -2.13 |